Aurinia Pharmaceuticals (AUPH) Current Assets (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Current Assets came in at $480.2 million in Q1 2026, up 18.36% YoY from $405.8 million in Q1 2025, and down 2.38% on a QoQ basis from $492.0 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Current Assets (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 11 years of Current Assets data on file, last reported at $480.2 million in Q1 2026.
- Quarterly Current Assets rose 18.36% year-over-year to $480.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $480.2 million (up 18.36% YoY) and the FY2025 annual result came in at $492.0 million, up 10.16% from the prior year.
- Current Assets slipped to $480.2 million in Q1 2026, from $492.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $492.0 million in Q4 2025 to a low of $398.2 million in Q1 2024.
- A 5-year average of $437.9 million and a median of $438.7 million in 2025 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 39.63% in 2022, down 13.79% in 2022.
- Tracing AUPH's Current Assets over 5 years: stood at $442.5 million in 2022, then slipped by 4.01% to $424.8 million in 2023, then advanced by 5.13% to $446.6 million in 2024, then climbed by 10.16% to $492.0 million in 2025, then dropped by 2.38% to $480.2 million in 2026.
- The last three Current Assets figures came in at $480.2 million (Q1 2026), $492.0 million (Q4 2025), and $438.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 541.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 541.32 Mn |
| Mar 31, 2026 | 480.24 Mn |
| Dec 31, 2025 | 491.97 Mn |
| Sep 30, 2025 | 438.74 Mn |
| Jun 30, 2025 | 408.97 Mn |
| Mar 31, 2025 | 405.76 Mn |
| Dec 31, 2024 | 446.60 Mn |
| Sep 30, 2024 | 440.46 Mn |
| Jun 30, 2024 | 409.67 Mn |
| Mar 31, 2024 | 398.22 Mn |
| Dec 31, 2023 | 424.80 Mn |
| Sep 30, 2023 | 426.47 Mn |
| Jun 30, 2023 | 415.91 Mn |
| Mar 31, 2023 | 423.65 Mn |
| Dec 31, 2022 | 442.54 Mn |
| Sep 30, 2022 | 459.70 Mn |
| Jun 30, 2022 | 453.19 Mn |
| Mar 31, 2022 | 477.62 Mn |
| Dec 31, 2021 | 513.32 Mn |
| Sep 30, 2021 | 329.22 Mn |